Proteomics International Laboratories (PIQ) H1 2026 earnings summary

Executive summary

• Transitioned from development to early commercial execution, launching PromarkerⓇD and PromarkerⓇEso in Australia and establishing US reimbursement pricing for PromarkerⓇD effective January 2026.

• Expanded regulated laboratory capabilities in Australia and the US, and strengthened global intellectual property, including new US and Canadian patents for PromarkerⓇEso.

• Early commercial revenues generated from controlled market launches, with strategic focus on commercial execution, clinical validation, and reimbursement progress.

• Leadership transition with appointment of new CEO and addition of an independent Non-Executive Director.

Financial highlights

• Revenue and other income for the half-year ended 31 December 2025 was $868,749, down 10% year-over-year.

• Total expenses increased 27% to $6,934,776 compared to the prior year period.

• Net loss before income tax was $6,066,027, a 35% increase from the previous year.

• Net cash outflow from operating activities was $950,221, a 21% improvement year-over-year.

• Cash and cash equivalents at period end were $7,669,698, down from $11,036,820 at 30 June 2025.

Outlook and guidance

• Priorities for FY26 H2 include advancing US distribution partnerships, progressing reimbursement and coverage for PromarkerⓇD, and launching PromarkerⓇEso in the US.

• Focus on completing validation for PromarkerⓇEndo and evaluating commercial pathways for OxiDx.

• Emphasis on cost control, risk management, and building commercial teams in core markets.